LNTH Stock Overview
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lantheus Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$102.00 |
| 52 Week High | US$126.89 |
| 52 Week Low | US$59.56 |
| Beta | 0.20 |
| 1 Month Change | 0.89% |
| 3 Month Change | 10.13% |
| 1 Year Change | 69.29% |
| 3 Year Change | 67.82% |
| 5 Year Change | 668.07% |
| Change since IPO | 1,486.31% |
Recent News & Updates
Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry
Mar 07Lacklustre Performance Is Driving Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Low P/E
Feb 13
Lantheus Holdings (NASDAQ:LNTH) Seems To Use Debt Rather Sparingly
Jan 26Recent updates
Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry
Mar 07Lacklustre Performance Is Driving Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Low P/E
Feb 13Lantheus Holdings (NASDAQ:LNTH) Seems To Use Debt Rather Sparingly
Jan 26Lantheus Holdings: Powerhouse Potential In 2025
Jan 02If EPS Growth Is Important To You, Lantheus Holdings (NASDAQ:LNTH) Presents An Opportunity
Dec 21Lantheus Holdings' (NASDAQ:LNTH) Earnings Are Weaker Than They Seem
Nov 13Lantheus Holdings: Q3 Results Were Good But Market Overreacted
Nov 08Investors Still Waiting For A Pull Back In Lantheus Holdings, Inc. (NASDAQ:LNTH)
Nov 03Lantheus: PYLARIFY's Enhanced Prospects Are Welcome, But Don't Get Too Greedy Now
Oct 21Lantheus Holdings (NASDAQ:LNTH) Is Achieving High Returns On Its Capital
Oct 16We Think Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt With Ease
Sep 28
PYLARIFY's Strategic Moves Foster Growth In Oncology And Alzheimer's Markets
Aug 28 Expansion into the Alzheimer's diagnostic space and strategic acquisitions suggest diversification and potential for long-term growth in revenue sources.Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)
Aug 12Here's Why Lantheus Holdings (NASDAQ:LNTH) Has Caught The Eye Of Investors
Aug 05Investors Appear Satisfied With Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Prospects As Shares Rocket 49%
Jul 17Lantheus Holdings (NASDAQ:LNTH) Is Investing Its Capital With Increasing Efficiency
Jul 16Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt
Jun 24Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus
May 23Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce
May 10Lantheus Holdings: Powerful First Quarter
May 05Lantheus Holdings: Undervalued With A Good Outlook
Feb 28Shareholder Returns
| LNTH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.9% | 1.9% | 5.8% |
| 1Y | 69.3% | 1.7% | 4.8% |
Return vs Industry: LNTH exceeded the US Medical Equipment industry which returned 1.7% over the past year.
Return vs Market: LNTH exceeded the US Market which returned 4.8% over the past year.
Price Volatility
| LNTH volatility | |
|---|---|
| LNTH Average Weekly Movement | 7.9% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: LNTH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LNTH's weekly volatility (8%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 808 | Brian Markison | www.lantheus.com |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart.
Lantheus Holdings, Inc. Fundamentals Summary
| LNTH fundamental statistics | |
|---|---|
| Market cap | US$7.00b |
| Earnings (TTM) | US$312.44m |
| Revenue (TTM) | US$1.53b |
22.4x
P/E Ratio4.6x
P/S RatioIs LNTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LNTH income statement (TTM) | |
|---|---|
| Revenue | US$1.53b |
| Cost of Revenue | US$545.62m |
| Gross Profit | US$988.29m |
| Other Expenses | US$675.85m |
| Earnings | US$312.44m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.55 |
| Gross Margin | 64.43% |
| Net Profit Margin | 20.37% |
| Debt/Equity Ratio | 51.9% |
How did LNTH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 10:24 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lantheus Holdings, Inc. is covered by 23 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Yuan Zhi | B. Riley Securities, Inc. |
| Brian Kemp Dolliver | Brookline Capital Markets |